Differential interactions of the catalytic subunits of adenylyl cyclase with forskolin analogs

Biochemical Pharmacology

Volumn 78, Issue 1, 2009, Pages 62-69

  Pinto, Cibele ^a   Hübner, Melanie ^b   Gille, Andreas ^a   Richter, Mark ^a   Mou, Tung Chung ^c   Sprang, Stephen R ^c   Seifert, Roland ^d  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF MONTANA   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adenylyl cyclase; Diterpenes; Fluorescence spectroscopy; Forskolin; MANT GTP

Indexed keywords

1 DEOXYFORSKOLIN; 1,9 DIDEOXYFORSKOLIN; 6 ACETYL 7 DEACETYLFORSKOLIN; 7 DEACETYL 1 DEOXYFORSKOLIN; 7 DEACETYL 1,9 DIDEOXYFORSKOLIN; 7 DEACETYL 7 (N METHYLPIPERAZINO GAMMA BUTYRYLOXY)FORSKOLIN; 7 DEACETYLFORSKOLIN; 9 DEOXYFORSKOLIN; ADENYLATE CYCLASE; DITERPENE; FORSKOLIN; FORSKOLIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUORESCENCE SPECTROSCOPY; HYDROGEN BOND; HYDROPHOBICITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADENYLATE CYCLASE; FORSKOLIN; GTP-BINDING PROTEINS; GUANOSINE TRIPHOSPHATE; KINETICS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN SUBUNITS; SPECTROMETRY, FLUORESCENCE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67349241188     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.03.023     Document Type: Article

References (23)

1. Sunahara R.K., Dessauer C.W., and Gilman A.G. Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 36 (1996) 461-480
2. Tang W.J., and Hurley J.H. Catalytic mechanism and regulation of mammalian adenylyl cyclases. Mol Pharmacol 54 (1998) 231-240
3. Hanoune J., and Defer N. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 41 (2001) 145-174
4. Seamon K.B., and Daly J.W. Forskolin: its biological and chemical properties. Adv Cyclic Nucleotide Protein Phosphorylation Res 20 (1986) 1-150
5. Laurenza A., Sutkowski E.M., and Seamon K.B. Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action?. Trends Pharmacol Sci 10 (1989) 442-447
6. Robbins J.D., Boring D.L., Tang W.J., Shank R., and Seamon K.B. Forskolin carbamates: binding and activation studies with type I adenylyl cyclase. J Med Chem 39 (1996) 2745-2752
7. Iwatsubo K., Tsunematsu T., and Ishikawa Y. Isoform-specific regulation of adenylyl cyclase: a potential target in future pharmacotherapy. Expert Opin Ther Targets 7 (2003) 441-451
8. Onda T., Hashimoto Y., Nagai M., Kuramochi H., Saito S., Yamazaki H., et al. Type-specific regulation of adenylyl cyclase. Selective pharmacological stimulation and inhibition of adenylyl cyclase isoforms. J Biol Chem 276 (2001) 47785-47793
9. Pinto C., Papa D., Hübner M., Mou T.C., Lushington G.H., and Seifert R. Activation and inhibition of adenylyl cyclase isoforms by forskolin analogs. J Pharmacol Exp Ther 325 (2008) 27-36
10. Dessauer C.W., Scully T.T., and Gilman A.G. Interactions of forskolin and ATP with the cytosolic domains of mammalian adenylyl cyclase. J Biol Chem 272 (1997) 22272-22277
11. sα with the cytosolic domains of mammalian adenylyl cyclase. J Biol Chem 272 (1997) 22265-22271
12. sα-GTPγS. Science 278 (1997) 1907-1916
13. Mou T.C., Gille A., Fancy D.A., Seifert R., and Sprang S.R. Structural basis for the inhibition of mammalian membrane adenylyl cyclase by 2′(3′)-O-(N-methylanthraniloyl)-guanosine 5′-triphosphate. J Biol Chem 280 (2005) 7253-7261
14. Mou T.C., Gille A., Suryanarayana S., Richter M., Seifert R., and Sprang S.R. Broad specificity of mammalian adenylyl cyclase for interaction with 2′, 3′-substituted purine- and pyrimidine nucleotide inhibitors. Mol Pharmacol 70 (2006) 878-886
15. Laurenza A., Khandelwal Y., De Souza N.J., Rupp R.H., Metzger H., and Seamon K.B. Stimulation of adenylate cyclase by water-soluble analogues of forskolin. Mol Pharmacol 32 (1987) 133-139
16. Zhang G., Liu Y., Ruoho A.E., and Hurley J.H. Structure of the adenylyl cyclase catalytic core. Nature 386 (1997) 247-253
17. Seamon K.B., Daly J.W., Metzger H., de Souza N.J., and Reden J. Structure-activity relationships for activation of adenylate cyclase by the diterpene forskolin and its derivatives. J Med Chem 26 (1983) 436-439
18. 3H]forskolin to rat brain membranes. Proc Natl Acad Sci USA 81 (1984) 5081-5085
19. Seifert R., and Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn-Schmiedeberg's Arch Pharmacol 366 (2002) 381-416
20. Neubig R.R., Spedding M., Kenakin T., and Christopoulos A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55 (2003) 597-606
21. Kenakin T., Jenkinson S., and Watson C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319 (2006) 710-723
22. Gille A., Lushington G.H., Mou T.C., Doughty M.B., Johnson R.A., and Seifert R. Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides. J Biol Chem 279 (2004) 19955-19969
23. Göttle M, Geduhn J, König B, Gille A, Höcherl K, Seifert R. Characterization of mouse heart adenylyl cyclase. J Pharmacol Exp Ther 2009; in press.